{
    "Clinical Trial ID": "NCT01326481",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Carotuximab (TRC105) Plus Capecitabine",
        "  All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically proven advanced solid cancer for which curative therapy is not available (Part 1 only)",
        "  Histologically proven metastatic Her-2-negative breast cancer (Part 2 only)",
        "  Measurable disease by RECIST 1.1 criteria (Part 2 only)",
        "  Willing and able to consent for self to participate in study",
        "  Progressive or recurrent disease after prior systemic chemotherapy regimen",
        "  Age  18 years",
        "  ECOG performance status of 0 or 1",
        "  Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade  1 or baseline (except alopecia)",
        "  Adequate organ function",
        "Exclusion Criteria:",
        "  Prior treatment with more than one systemic chemotherapy regimen for metastatic disease.",
        "  Prior treatment with TRC105",
        "  History of hypersensitivity reaction to antimetabolite therapy",
        "  Receipt of an investigational agent within 28 days of starting study treatment",
        "  Prior surgery (including open biopsy), radiation therapy or systemic therapy within 28 days of starting study treatment",
        "  Minor surgical procedures within 14 days prior to first dose of TRC105",
        "  History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease",
        "  Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months",
        "  Uncontrolled chronic hypertension defined as systolic > 140 or diastolic > 90 despite optimal therapy",
        "  Past medical history of acquired or inherited coagulopathy including patients with known hereditary hemorrhagic telangiectasia",
        "  Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to first dose with TRC105",
        "  Cardiac dysrhythmias of NCI CTCAE Grade  2 within the last month",
        "  Hemorrhage within 28 days of starting study treatment",
        "  Unhealed wounds within 28 days of starting study treatment",
        "  History of peptic ulcer disease or gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment",
        "  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness",
        "  Known active viral or nonviral hepatitis",
        "  History of hypersensitivity reaction to human or mouse antibody products",
        "  Lung cancer with central chest lesions",
        "  Pregnancy or breastfeeding"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine",
        "  Assess safety and dose limiting toxicity by dose cohort and coding all terms utilized MedDRA version 14.1.",
        "  Time frame: 1.5 years",
        "Results 1: ",
        "  Arm/Group Title: Carotuximab (TRC105) Plus Capecitabine",
        "  Arm/Group Description: All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Patients with DLT at 7.5 mg/kg: 0   0.0%",
        "  Patients without DLT at 7.5 mg/kg: 3  50.0%",
        "  Patients with DLT at 10 mg/kg: 0   0.0%",
        "  Patients without DLT at 10 mg/kg: 3  50.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 6/19 (31.58%)",
        "  Febrile neutropenia  [1]1/19 (5.26%)",
        "  Fatigue  [1]1/19 (5.26%)",
        "  Pyrexia  [1]1/19 (5.26%)",
        "  Fracture  [1]1/19 (5.26%)",
        "  Hip Fracture  [1]1/19 (5.26%)",
        "  Headache  [2]1/19 (5.26%)"
    ]
}